US EditionNew NHS bladder cancer treatment doubles survival time
The new NHS-approved therapy doubles overall and progression-free survival compared to chemotherapy, benefiting an estimated 1,250 advanced bladder cancer patients annually in England.
- This month, the National Institute for Health and Care Excellence recommended the enfortumab vedotin and pembrolizumab combination for NHS use in England and Wales, targeting patients with unresectable or metastatic urothelial cancer and doubling survival time versus standard care.
- Experts note that treatment for advanced bladder cancer had not changed since the 1980s, with only 29% surviving a year and around 12% five-year survival rates under the historical standard: platinum-based chemotherapy.
- Trial data showed in the EV-302 global phase 3 trial that enfortumab vedotin plus pembrolizumab doubled progression-free survival to 12.5 months and improved median overall survival to 31.5 months versus chemotherapy.
- The rollout means around 1,250 eligible patients in England each year can access the treatment, which NICE called cost-effective due to NHS deals with Astellas Pharma and MSD UK, and clinicians report fewer side effects compared to chemotherapy.
- This approval follows NICE's second recommendation this year for advanced bladder cancer therapies and earlier this month Astellas and Pfizer reported EV-303 results expanding Padcev/Keytruda research.
Insights by Ground AI
Does this summary seem wrong?
15 Articles
15 Articles
Evening Standard+4 Reposted by 4 other sources
First new treatment for advanced bladder cancer in decades given green light
Experts said the approval of the new treatment combination would bring a ‘fundamental shift’ in care for patients with late-stage disease.
·London, United Kingdom
Read Full ArticleCoverage Details
Total News Sources15
Leaning Left3Leaning Right1Center5Last UpdatedBias Distribution56% Center
Bias Distribution
- 56% of the sources are Center
56% Center
L 33%
C 56%
11%
Factuality
To view factuality data please Upgrade to Premium
